Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive JNJ-40411813 for focal onset seizures with inadequate response to levetiracetam or brivaracetam
2020-003698-24Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy and Focal onset seizure comparing JNJ-40411813 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Time to baseline monthly seizure count. Started Mar 2021; status: completed.
02
Drugs
adx-71149
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on 2020-003698-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003698-24.